PALO ALTO, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) — Cognoa, a company offering an AI-based platform for pediatric behavioral health diagnostics and digital therapeutics, announces that the U.S. Food and Drug Administration (FDA) has established that Cognoa’s software is a Class II diagnostic medical device for autism. This milestone will expand Cognoa’s ability to offer its solution to enterprise customers,…

PALO ALTO, CA–(Marketwired – Jun 14, 2017) – Cognoa, a digital health company revolutionizing how children with developmental delays are diagnosed and supported, today announces Sharief Taraman, MD as its vice president of medical and clinical. Dr. Taraman will lead the company’s further clinical validation of Cognoa’s child development software for payers and employers as well as the company’s U.S. Food…